Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging

[1]  G. Cocconi,et al.  Problems in evaluating response of primary breast cancer to systemic therapy , 2005, Breast Cancer Research and Treatment.

[2]  Min-Ying Su,et al.  Monitoring the Size and Response of Locally Advanced Breast Cancers to Neoadjuvant Chemotherapy (Weekly Paclitaxel and Epirubicin) with Serial Enhanced MRI , 2003, Breast Cancer Research and Treatment.

[3]  P J Drew,et al.  Current applications and future direction of MR mammography , 2003, British Journal of Cancer.

[4]  H. Junkermann,et al.  Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy , 2003, European Radiology.

[5]  P. Belli,et al.  Role of magnetic resonance imaging in inflammatory carcinoma of the breast. , 2002, Rays.

[6]  A. Padhani,et al.  Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.

[7]  Fiona J Gilbert,et al.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Zuna,et al.  Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution , 2002, European Radiology.

[9]  A. Rieber,et al.  Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy , 2002, European Radiology.

[10]  G J Metzger,et al.  MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with x‐ray mammography and palpation , 2001, Journal of magnetic resonance imaging : JMRI.

[11]  Ying Lu,et al.  MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer , 2001, Annals of Surgical Oncology.

[12]  W E Reddick,et al.  Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. , 2000, Advanced drug delivery reviews.

[13]  S. Delorme,et al.  Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. , 2000, Anticancer research.

[14]  G. Hortobagyi,et al.  Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M V Knopp,et al.  Evaluation of angiogenesis and perfusion of bone marrow lesions: Role of semiquantitative and quantitative dynamic MRI , 1999, Journal of magnetic resonance imaging : JMRI.

[16]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[17]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[18]  M. Christian,et al.  Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.

[19]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M V Knopp,et al.  Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Bonadonna,et al.  Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Knopp,et al.  [Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography]. , 1997, Der Radiologe.

[24]  G. Brix,et al.  Methods for quantitative assessment of tissue microcirculation using dynamic contrast-enhanced MR imaging , 1997, Der Radiologe.

[25]  S E Harms,et al.  Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging , 1996, Cancer.

[26]  J E Husband,et al.  Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. , 1996, Radiology.

[27]  W E Reddick,et al.  Dynamic contrast‐enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy , 1995, Journal of magnetic resonance imaging : JMRI.

[28]  J. Hogg.  Magnetic resonance imaging. , 1994, Journal of the Royal Naval Medical Service.

[29]  Q. Han,et al.  [Management of stage III primary breast cancer. An analysis of 221 cases]. , 1992, Zhonghua wai ke za zhi [Chinese journal of surgery].

[30]  G. Hortobagyi,et al.  Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.

[31]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[32]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.